Testing Doses and Treatment Timelines of Anti-Angiogenic Drug Bevacizumab Numerically as a Single-Agent for the Treatment of Ovarian Cancer

Dharma Raj Khatiwada () and Miana Wallace
Additional contact information
Dharma Raj Khatiwada: School of STEM, College of Agriculture, Community and the Sciences, Kentucky State University, 400 E Main St, Frankfort, KY 40601, USA
Miana Wallace: School of STEM, College of Agriculture, Community and the Sciences, Kentucky State University, 400 E Main St, Frankfort, KY 40601, USA

Mathematics, 2023, vol. 11, issue 2, 1-6

Abstract: An anti-angiogenic drug in cancer treatment prevents the growth of new blood vessels in tumors by binding to VEGF molecules, which otherwise induce endothelial cells inside blood vessels to sprout the blood supply toward the tumor. This would prevent the growth of new blood cells which will deprive the tumor of nutrients, thus decreasing its carrying capacity, and ultimately shrinking its volume. With new vascularization absent, the tumor will be isolated, making it easier to treat. Although there is an availability of various anti-angiogenic drugs, their effectiveness is low compared to other cancer treatments. We are specifically pinpointing the various combination of doses and the treatment timelines as reasonable factors to increase the effectiveness of the anti-angiogenic drug Bevacizumab, which can possibly prolong the patient’s survival rate and offer lower toxicity compared to other treatment modalities such as radiotherapy and chemotherapy. We have numerically analyzed different doses of Bevacizumab, including 15 mg/kg, an FDA-approved dose if offered in conjunction with chemotherapy drugs, carboplatin and paclitaxel, as a single-agent treatment option. Based on the results, the tumor volume was observed to be stabilizing for the duration of the treatment, which was chosen to be 400 days. The toxicity levels of these doses with Bevacizumab as a single-agent treatment option have not been tested in a clinical setting. However, these mathematically promising results can provide a gateway for the successful treatment of ovarian cancer in the future.

Keywords: ovarian cancer; numerical analysis; anti-angiogenic drug; Bevacizumab; single-agent treatment option; toxicity (search for similar items in EconPapers)
JEL-codes: C (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2227-7390/11/2/358/pdf (application/pdf)
https://www.mdpi.com/2227-7390/11/2/358/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jmathe:v:11:y:2023:i:2:p:358-:d:1030743

Access Statistics for this article

Mathematics is currently edited by Ms. Emma He

More articles in Mathematics from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().